using Kaplan-Meier estimates. Additional data from the Dutch Comprehensive Cancer Centres (stage IV only) were used to compare survival outcomes in two time periods (2003-2011 versus 2012-2015). **RESULTS:** From 2012-2015, 1259 patients received systemic treatment (median follow-up 12.6 months; data cut-off March 09, 2015). The most frequently prescribed treatments were ipilimumab (29%) and vemurafenib (29%), followed by trial-based treatments (27%), chemotherapy (11%), and dabrafenib (4%). Vemurafenib was the most frequently applied treatment in the first line (41%), ipilimumab in the second line (56%), and trial-based treatments in the third and fourth line (41% and 63%, respectively). The median TTNT was 5.4, 4.7 and 4.3 months in the first, second, and third line, respectively. The median OS was 9.6 months (IQR 4.6-18.6) and the one-year survival was 41% (unresectable stage IIIc [n=33]: median OS 32.8 months, one-year survival 71%; stage IV [n=1226]: median OS 9.3 months, one-year survival 40%). In contrast, survival outcomes of stage IV melanoma were much lower in the period before the introduction of new drugs (2003-2011: median OS 6.8 months, one-year OS 33%). CONCLUSIONS: Melanoma survival has improved since the introduction of new drugs for advanced melanoma. The survival gain shown in pivotal trials was also observed in real-world clinical practice in The Netherlands.

PCN65

MORTALITY TRENDS IN CANCERS: A NEW MODEL TO VISUALISE THE CONTRIBUTION OF SPECIFIC DISEASES, COHORTS AND CODING CHANGES TO OVERALL MORTALITY IMPROVEMENT Martin C, Martin A

Crystallise Ltd., London, UK

OBJECTIVES: Identifying the drivers of trends in mortality for disease classes is challenging. We used the Requiem model to visualise trends by gender and age in 3-D format to identify cohort and other effects in specific cancers. **METHODS:** The Requiem model analysed and smoothed ONS mortality statistics for England and Wales from 1970 to 2013 by single year of age and gender. Disease codes were mapped at 4-digit level from ICD-8 to ICD-10 by medical modellers. An analysis was run for total cancer mortality and individual malignant diseases within that category. Outputs were displayed in multiple formats, including 3-D images of central mortality and deaths by age over time, and heat maps of absolute mortality improvement per disease and the component each disease contributed to all-cause mortality trends. RESULTS: Cancer mortality increased from 1970 to 1990s and has since fallen by up to 4% per year, accounting for a 1-2% of absolute improvement in all-cause mortality, and with evidence from heat maps for cohort effects. Most cancers showed increasing mortality rates to the 1990s, which have now declined. This is seen particularly in men in lung cancer, which saw up to 10% improvement per year in mortality, in breast cancer in women, with a peak in the 1980s and up to 20% annual improvement since then, and in colon cancer in both genders, with a 5-10% annual improvement in mortality per year. Hodgkin's lymphoma mortality has decreased steadily in both genders, while non-Hodgkin's mortality has increased in the over 50s. Mortality continues to worsen for liver, kidney and CNS cancers. Pancreatic cancer has shown little change in mortality since 1970 in either gender. CONCLUSIONS: The Requiem model 3-D visualisation facilitates the understanding of trends in mortality for different cancers, and shows the impact of cohort effects and risk factors such as smoking and alcohol.

PCN66

EVALUATION OF 'REAL-WORLD' IPILIMUMAB DATA IN IRELAND

McCullagh LM¹, Adams R¹, Barry M¹, Schmitz S², Walsh C³

¹National Centre for Pharmacoeconomics, Dublin, Ireland, ²Trinity College Dublin, Dublin, Ireland, ³University of Limerick, Limerick, Ireland

OBJECTIVES: Ipilimumab is licensed for the treatment of adults with advanced (unresectable or metastatic) malignant melanoma. It was approved for reimbursement in Ireland in 2012, through the Oncology Drug Management System (ODMS). The ODMS was introduced by the National Cancer Control programme in July 2012. The scheme allows direct hospital reimbursement for approved high cost anti-cancer drugs for individual patients. Drugs must be prescribed for approved indications accord ing to license informed protocols. The online based system is designed to collect information from hospitals (26 nationally) in relation to patient demographic data, cancer drug use and spending. This data is maintained by the payer (Primary Care Reimbursement Service (PCRS)). The objective of this study is to examine this real world data of patients treated with ipilimumab. **METHODS:** The PCRS extracted data on all patients who had received ≥1 dose of ipilimumab (June 2012 - May 2015) in the public hospital setting through the ODMS. Patient data included patient demographics, the quantity of ipilimumab supplied and the reimbursement claim data. The National Centre for Pharmacoeconomics analysed this anonymised data. Kaplan-Meier survival curves were constructed using the Tierney et al methodology. Survival data was extrapolated using the Hoyle and Henley methodology. RESULTS: A total of 205 patients who had received ≥ 1 dose ipilimumab over the period of analysis were identified. The mean age of the cohort was 60.4 years (SD $\pm 14)$ and 58.5% were male. All 4 cycles of ipilimumab were received by 59% of patients. Seven patients were re-treated with the drug. Empirical and extrapolated real world survival data were compared to clinical trial evidence. CONCLUSIONS: The analysis provides real world survival outcomes for patients with advanced malignant melanoma treated with ipilimumab in Ireland. Examination of this evidence is prudent in advance of the launch of the PD1 inhibitors for malignant melanoma.

PCN67

RETROSPECTIVE COMPARISON OF REAL-LIFE SURVIVAL DATA FROM SINGLE CENTRE TRIALS - THE CLINICAL OUTCOME OF VEMURAFENIB THERAPY IN METASTATIC MELANOMA PATIENTS

Porneczy E¹, Czirbesz K¹, Toth E¹, Liszkay G¹, Boncz I²

¹National Institute of Oncology, Budapest, Hungary, ²University of Pecs, Pecs, Hungary OBJECTIVES: The selection of the MM patient group, eligible for BRAFi therapy is based on the molecular pathologic diagnostics of the BRAF V600 gain-of-function

mutation. The sensitivity and specificity of Cobas 4800 BRAF V600 in vitro diagnostic test is excessively high to detect the V600 mutation. In the BRIM-3 study, vemurafenib showed improved PFS and OS in patients carrying BRAF mutation. Our aim is to analyze the vemurafenib international and local real-life survival data of the patients treated in the National Institute of Oncology, in case of individual reimbursement application. METHODS: We retrospectively assessed the single centre Hungarian real-life survival data from 2012 to May 2015. We compared the outcome of the Hungarian and the French real-life and BRIM-3 data. RESULTS: In the selection of the patient group suitable for BRAFi therapy, we carried out 277 BRAF mutation analysis with Cobas test during the given period. 148 cases were wide type, the mutation rate was 46,57% with 129 mutant cases. In Hungary, BRAFi therapy is reimbursed, only on the basis of individual reimbursement application. 36 MM patients were enrolled, with median age of 53,5 years. The median PFS reached 5,4 months, the OS reached 12,3 months. In the previously published French single centre trial, in temporary authorisation program, the median PFS was 3,6 months, the median OS was 7,5 months. The BRIM-3 study demonstrated mPFS 6,9 months and OS 13,6 months. CONCLUSIONS: The detection of BRAF mutation is essential in the therapeutic strategy of metastatic melanoma patients. The Cobas 4800 BRAF test allows a more exact selection of the patient group to be treated by BRAFi. Our single centre OS data are close to BRIM3 clinical trial data. In case of previous vemurafenib therapy started in appropriate treatment line, further improvement can be expected in survival results

CANCER - Cost Studies

PCN68

THE BUDGET IMPACT OF DENOSUMAB IN THE TREATMENT OF GIANT CELL TUMOR OF THE BONE (GCTB) IN BELGIUM

Cristino J¹, Fikkert V², Flament A², Vingerhoedt S², Qian Y³

¹Amgen (Europe) GmbH, Zug, Switzerland, ²Amgen Belgium, Brussels, Belgium, ³Amgen Inc., Thousand Oaks, CA, USA

OBJECTIVES: To estimate the budget impact in Belgium of denosumab (120 mg) in the treatment of GCTB, an extremely rare, locally aggressive benign tumor often leading to severe destruction of bone and extension into the surrounding soft tissues. METHODS: A budget impact model was developed, combining epidemiological data, proportions of resectable and unresectable GCTB disease, and eligibility for treatment with denosumab. Evidence collected in clinical trials is used to estimate the denosumab clinical effect. Publicly available costs of the relevant surgical procedures and the actual cost for denosumab 120 mg from payer perspective are considered. The clinical effect of denosumab in delaying or downgrading invasive surgeries is estimated by comparing the surgical procedures planned at trial entry and the procedures actually performed during the trial. To calculate the savings in surgical procedures, the downgrade in planned procedures and only 50% of the avoided procedures in the trial period were considered. Resource use associated with the surgical procedures included the need for rehabilitation and re-hospitalizations due to complications. Savings were only applied to patients with resectable tumors. The model does not take into account the full clinical benefit of denosumab including decrease in disease progression in patients who have not undergone surgery. The time horizon considered was 3 years. **RESULTS:** Denosumab is expected to be provided to 32, 42 and 53 patients in year 1, 2 and 3, respectively. 550,940 euros of total drug expenditure are expected. Savings were estimated at 409,372 euros, the majority of which was attributable to fewer and less severesurgical procedures. The impact of denosumab on the overall health care budget is 141,568 euros over three years. CONCLUSIONS: The introduction of denosumab in the treatment of GCTB has a manageable budget impact in Belgium. Seventy four percent of the denosumab expenditure is off-set thanks to its clinical benefit.

PCN69

BUDGET IMPACT ANALYSIS OF DASATINIB AS A SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE RUSSIAN FEDERATION

Kulikov A, Yagudina R, Protsenko MV

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

OBJECTIVES: CML is among seven nosologies included in the federal program for supply of medicines to patients with rare diseases in the Russian Federation. Currently only first-generation tyrosine kinase inhibitor - imatinib is available to CML patients within this program. However from 25% to 30% of CML patients in Russia have intolerance or develop resistance to imatinib and require second line therapy with dasatinib or nilotinib. METHODS: This study includes budget impact analysis (BIA) for dasatinib as a second-line CML therapy. Only direct pharmacotherapy costs were considered. Annual treatment cost of dasatinib amounts to 1,720,111 rubles (28,365 €) for chronic phase. Time horizon was set at 1 year. In the baseline scenario it was assumed that 100% of the imatinib-resistant patients are treated with high-dose imatinib in frame of the federal "seven nosologies" program. In the future scenario upon dasatinib inclusion into aforementioned program the percentage of patients that would be possible to switch from highdose imatinib to dasatinib without increase of the total national CML budget was calculated. Also annual economic impact of providing dasatinib as a second-line therapy to 100% of the eligible patients was estimated. Assumptions regarding adherence to treatment of patients diagnosed with CML and actual medica-tion consumption rate were included into analysis. **RESULTS:** Budget impact analysis was carried out for a total population of 7100 patients according to the national CML registry in 2015. Centralized purchase of dasatinib in frame of the federal program could save 463 mln rubles (7,7 mln €) or 10% of the actual total CML budget in Russia. CONCLUSIONS: With consideration for actual dasatinib use within regional drug provision programs it was demonstrated that 100% of the imatinib-resistant and intolerant patients can be provided with dasatinib